{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:31:05Z","timestamp":1790112665801,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM), the most malignant central nervous system cancer, has a median survival rate of 14\u201316\u00a0months. GBM patients have a poor prognosis despite rigorous multi-modal treatments like surgical resection, chemotherapy, and radiation. A systematic bioinformatics analysis of GXA gene expression datasets showed thirty-three overexpressed genes in GBM that were enriched in neuroactive ligand receptor interaction. Subsequently, bulk brain tissue gene expression profiling showed high to moderate expression of CCK, VGF, APLN, CNR1, GRIA4, and PDYN in the cortex, frontal cortex-BA9, BA24 region, cerebellar hemisphere, cerebellum, hippocampus, amygdala, basal ganglia, hypothalamus, substantia nigra, and spinal cord. Interesting, the cortex, frontal cortex-BA9, and BA24 regions had unbelievably high CCK expression. Brain cortex and frontal lobe mutational scoring showed significant rates of IDH1 (49%), TERT (25%), SETD2 (17%), and BRAF (9%). We initially confirmed glioblastoma (GBM) malignancy and therapeutic responses to CCK overexpression and IDH1 mutations in cerebral cortex and frontal cortex tissue samples. However, Mann\u2013Whitney analysis revealed ZBTB20 mutations cause CCK expression, not IDH1 mutations. Overall, CCK expression and ZBTB20 mutations may be used in therapeutic treatments as predictive and diagnostic markers. The expression of CCK was not linked with overall survival and excludes its potential application as prognostic biomarker for GBM. This study showed that CCK and ZBTB20 based predictive and diagnostic technologies can improve precision and personalization of targeted cancer therapies for GBM patients. Nevertheless, experimental evidences have yet to reveal additional therapeutically meaningful connections between CCK expression and ZBTB20 mutations.<\/jats:p>","DOI":"10.1186\/s12920-025-02218-0","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:24:38Z","timestamp":1759843478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overexpression of CCK Neuropeptide in brain is linked to ZBTB20 mutations: potential diagnostic relevance in glioblastoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Tikam Chand","family":"Dakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarek","family":"Maciaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"6","key":"2218_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"26","key":"2218_CR2","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"Comprehensive","year":"2015","unstructured":"Comprehensive. Integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"2218_CR3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550\u201363.","journal-title":"Cell"},{"issue":"26","key":"2218_CR4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, et al. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499\u2013508.","journal-title":"N Engl J Med"},{"issue":"2","key":"2218_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11910-017-0722-5","volume":"17","author":"M Karsy","year":"2017","unstructured":"Karsy M, et al. New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Curr Neurol Neurosci Rep. 2017;17(2):19.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6167","key":"2218_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189\u201393.","journal-title":"Science"},{"issue":"2","key":"2218_CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ijc.33283","volume":"148","author":"\u00c1 Nagy","year":"2021","unstructured":"Nagy \u00c1, Gy\u0151rffy B. Mutarget: a platform linking gene expression changes and mutation status in solid tumors. Int J Cancer. 2021;148(2):502\u201311.","journal-title":"Int J Cancer"},{"issue":"2","key":"2218_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ccell.2018.12.010","volume":"35","author":"AA Connor","year":"2019","unstructured":"Connor AA, et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell. 2019;35(2):267-282.e7.","journal-title":"Cancer Cell"},{"issue":"5","key":"2218_CR9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1593\/neo.08206","volume":"10","author":"Y Lyustikman","year":"2008","unstructured":"Lyustikman Y, et al. Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia. 2008;10(5):501\u201310.","journal-title":"Neoplasia"},{"issue":"2","key":"2218_CR10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00401-007-0239-0","volume":"114","author":"J Jeuken","year":"2007","unstructured":"Jeuken J, et al. RAS\/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 2007;114(2):121\u201333.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2218_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10014-017-0302-z","volume":"35","author":"I Shibahara","year":"2018","unstructured":"Shibahara I, et al. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol. 2018;35(1):10\u20138.","journal-title":"Brain Tumor Pathol"},{"issue":"12","key":"2218_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nbt.1587","volume":"27","author":"JD Henson","year":"2009","unstructured":"Henson JD, et al. DNA c-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol. 2009;27(12):1181\u20135.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2218_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1750-3639.2008.00225.x","volume":"19","author":"AJ Sievert","year":"2009","unstructured":"Sievert AJ, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449\u201358.","journal-title":"Brain Pathol"},{"issue":"6","key":"2218_CR14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00401-013-1120-y","volume":"125","author":"S Dahiya","year":"2013","unstructured":"Dahiya S, et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol. 2013;125(6):901\u201310.","journal-title":"Acta Neuropathol"},{"issue":"7\u20138","key":"2218_CR15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.18632\/oncoscience.317","volume":"3","author":"J Cai","year":"2016","unstructured":"Cai J, et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience. 2016;3(7\u20138):258\u201365.","journal-title":"Oncoscience"},{"issue":"5","key":"2218_CR16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.celrep.2017.10.009","volume":"21","author":"AS Modrek","year":"2017","unstructured":"Modrek AS, et al. Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2. Cell Rep. 2017;21(5):1267\u201380.","journal-title":"Cell Rep"},{"issue":"10","key":"2218_CR17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.18632\/oncotarget.689","volume":"3","author":"K Kannan","year":"2012","unstructured":"Kannan K, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194\u2013203.","journal-title":"Oncotarget"},{"issue":"8","key":"2218_CR18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"5897","key":"2218_CR19","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807\u201312.","journal-title":"Science"},{"issue":"5","key":"2218_CR20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00401-012-1031-3","volume":"124","author":"XY Liu","year":"2012","unstructured":"Liu XY, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1\/IDH2 and TP53 mutations. Acta Neuropathol. 2012;124(5):615\u201325.","journal-title":"Acta Neuropathol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02218-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:58:00Z","timestamp":1781611080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-025-02218-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02218-0","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}